NCT04395677View on ClinicalTrials.gov

A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

173

Participants

Timeline

Start Date

July 7, 2020

Primary Completion Date

December 30, 2023

Study Completion Date

December 31, 2025

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

AB-106

"Stage 1: 400mg QD for 3 patients and 600mg QD for 3 patients~Stage 2: 600mg QD"

Trial Locations (1)

200000

Shanghai Pulmonary Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

AnHeart Therapeutics Inc.

INDUSTRY